Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01610856
Other study ID # 21972
Secondary ID Ethics ID 21972
Status Completed
Phase N/A
First received May 30, 2012
Last updated June 1, 2012
Start date March 2010
Est. completion date June 2010

Study information

Verified date May 2012
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Proper bowel cleansing prior is an essential requirement for the conduct of colonoscopy. However, due to the nature of cleansing process, the ideal bowel cleansing preparation remains elusive.

The objective of this study is to compare the efficacy, safety and tolerability of oral polyethylene glycol lavage given either as a single dose or split dose. The study will be a randomized controlled single blind two group study. The primary study outcomes will be the previously validated Ottawa bowel preparation score.


Description:

All patients between the age of 50 and 75 years referred to the Forzani & MacPhail Colorectal Cancer Screening Centre in Calgary, Alberta, Canada for colonoscopy will be considered for inclusion. During pre-assessments at the clinic, patients will be asked to participate in the study by a nurse clinician. If they agree - final consent will be obtained by a gastroenterologist along with consent for the colonoscopy. Those not interested in participating will simply receive their physicians standard bowel preparation protocol. There will be no coercion of any sort.

Patients with acute coronary syndrome, congestive heart failure, unstable angina, known or suspected renal failure, ascites, megacolon, known or suspected bowel obstruction, or other comorbidities that may prevent colonoscopy will be excluded. Patients will also be excluded if they previously had partial or subtotal colectomy or if the colonoscopy is warranted for the evaluation of diarrhea.

Enrollment of participants will be performed with block randomizations of 8 stratified by AM versus PM procedure time using a computer-generated table, with allocation concealment maintained through the use of consecutively numbered sealed envelopes. Colonoscopists and investigators will be blinded to allocation groups. Patients will be allocated to one of two groups: (1) 4L PEG day prior to procedure; (2) 4L of PEG split in two 2L doses

A study assistant will assign patients to their group and instruct them on the proper use of their assigned bowel preparation method. Patients will be given a tolerability questionnaire, that was modified from a previously reported questionnaire, to be completed once their bowel preparation is finished and before coming to the hospital for the colonoscopy. Patient concerns or questions regarding the preparation will be directed toward the assistant as opposed to their gastroenterologist, so as to avoid unblinding the gastroenterologist.

Outcomes

The previously validated Ottawa bowel preparation scale80 will be used to assess the quality of bowel cleanliness. Each of the right, mid and rectosigmoid colon is rated on a 5-point scale (0-4). In addition, a complete 3-point rating for overall colonic fluid is assessed resulting in an overall score range of 0 to 14. An excellent preparation with little fluid would score 0 to 1; a good preparation, 2 to 4; while scores higher than 4 would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11 to 14, depending on the amount of colonic fluid.

Colonoscopy will be performed in a standard fashion and endoscopists will rate the bowel-preparation quality during the procedure and record the result on a separate standardized form.

Secondary outcomes will include a previously validated tolerability questionnaire and patient and investigator reported adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria:

- All patients between the age of 50 and 75 years referred to the Forzani & MacPhail Colorectal Cancer Screening Centre in Calgary, Alberta, Canada for colonoscopy will be considered for inclusion.

Exclusion Criteria:

- patients with acute coronary syndrome,

- congestive heart failure,

- unstable angina,

- known or suspected renal failure,

- ascites,

- megacolon,

- known or suspected bowel obstruction, or

- other comorbidities that may prevent colonoscopy will be excluded. Patients will also be excluded if they previously had partial or subtotal colectomy or if the colonoscopy is warranted for the evaluation of diarrhea.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
Polyethylene Glycol
4 Litres of polyethylene glycol bowel preparation solution
polyethylene glycol
Polyethylene glycol 4L given in two split doses of 2L each

Locations

Country Name City State
Canada Forzani & MacPhail Colon Cancer Screening Centre Calgary Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Ottawa Bowel Preparation Score A validated scale. Each of the right, mid and rectosigmoid colon is rated on a 5-point scale (0-4). In addition, a complete 3-point rating for overall colonic fluid is assessed resulting in an overall score range of 0 to 14. An excellent preparation with little fluid would score 0 to 1; a good preparation, 2 to 4; while scores higher than 4 would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11 to 14, depending on the amount of colonic fluid. Measured at time of Colonoscopy Yes
See also
  Status Clinical Trial Phase
Terminated NCT01140295 - Bowel Preparation for Colonoscopy in Children Phase 4
Recruiting NCT03290157 - Improvement of Colonoscopy Preparation by Using a SPA N/A
Completed NCT04150133 - Effects and Tolerability With Clenpiq and Low Residue Diet N/A
Completed NCT01531140 - PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy Phase 4
Completed NCT06021639 - Comparison of Bowel Cleansing Regimens for Colonoscopy N/A
Completed NCT02073552 - Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Phase 4
Completed NCT01596686 - Comparison of Preparation Regimens for Colonoscopy N/A
Withdrawn NCT04361656 - The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation
Completed NCT02410720 - The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation N/A
Completed NCT01887470 - 2 Regimens of Lactulose for Colonoscopy Preparation in Adults Phase 2
Completed NCT06282367 - Bowel Preparation for Colonoscopy With Oral Lactulose
Completed NCT02304523 - Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy Phase 3
Completed NCT06453655 - The Effect of Nurse Process on Bowel Cleansing N/A
Completed NCT02665624 - Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation Phase 4
Completed NCT02123017 - Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy Phase 2